Cytokinetics, Inc. (CYTK)

[Paulieme]

YES!!! Cytokinetics Announces Clinical Trial Data Relating to CK-2017357 to Be Presented at the 64th Annual Meeting of the American Academy of Neurology
Additional Preclinical Trial Data to Be Presented at the 2012 Experimental Biology Conference

SOUTH SAN FRANCISCO, CA--(Marketwire -04/18/12)- Cytokinetics, Incorporated (NASDAQ: CYTK - News) announced today that one oral presentation and two poster presentations are scheduled to be presented at the 64th Annual Meeting of the American Academy of Neurology, to be held April 21-28, 2012 in New Orleans, LA. In addition, a poster presentation containing preclinical data relating to CK-2017357 is scheduled to be presented at the 2012 Experimental Biology Conference being held April 21-25, 2012 in San Diego, CA.

CK-2017357 is the lead drug candidate that has emerged from the company's skeletal muscle contractility program. CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input and delays the onset and reduces the degree of muscle fatigue.

Oral Presentation at the 64th Annual Meeting of the American Academy of Neurology

Date: Wednesday, April 25, 2012
Presentation Time: 2:00 PM - 3:45 PM Central Daylight Time
Presentation #: S25.005
Session: S25: Anterior Horn
Title: A Study to Evaluate Safety, and Tolerability of Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis
Presenter: Jeremy M. Shefner, MD, PhD, Professor and Chair, Department of Neurology at the Upstate Medical University, State University of New York

Poster Presentation at the 64th Annual Meeting of the American Academy of Neurology

Date: Wednesday, April 25, 2012
Presentation Time: 7:30 AM - 9:00 AM Central Daylight Time (poster displayed 7:30 AM - 12:00 PM)
Poster #: P04.155
Session: P04: Anterior Horn: Therapeutics
Title: A Study to Evaluate Safety and Tolerability of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily, Dose-Titration Regimen
Presenter: Jeremy M. Shefner, MD, PhD, Professor and Chair, Department of Neurology at the Upstate Medical University, State University of New York

Date: Wednesday, April 25, 2012
Presentation Time: 5:30 PM - 7:00 PM Central Daylight Time (poster displayed 2:00 PM - 7:00 PM)
Poster #: P05.169
Session: P05: Anterior Horn: Basic Science
Title: The Fast Skeletal Troponin Activator, CK-2017357, Increases Muscle Function and Survival in SOD1 (G93A) Mice; a Model of ALS
Presenter: Fady I. Malik, MD, PhD, FACC, Cytokinetics, South San Francisco, CA

Poster Presentation at 2012 Experimental Biology Conference:

Date: Wednesday, April 25, 2012
Presentation Time: 12:30 PM - 2:45 PM Pacific Daylight Time (poster displayed 7:30 AM - 5:30 PM)
Abstract #: S85 1121.7
Title: The Fast Skeletal Troponin Activator, CK-2017357, Improves Resistance to Fatigue in Healthy, Conscious Rats
Presenter: Adam R. Kennedy, PhD, Cytokinetics, South San Francisco, CA

http://finance.yahoo.com/news/cytokinetics-announces-clinical-trial-data-200000907.html